A recent analysis from the KRYSTAL-1 trial (adagrasib in KRAS G12C-mutant NSCLC) showed that co-occurring KEAP1 or STK11 mutations were associated with significantly worse outcomes on KRAS G12C inhibitor therapy [56]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.